The present study’s findings further demonstrate that FK866 lowers NAD+ and ATP levels and reduces the survival of CCA cells by preventing NAMPT activity in HuCCT1, KMCH, and EGI cells. This evidence concerns the gene NAMPT and cholangiocarcinoma.